肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

JCO：治疗相关心脏毒性及其对儿童患者预后的影响

2018-11-08 MedSci MedSci原创

儿童患者心脏毒性预后
关注

儿童急性髓性白血病治疗后的晚期心脏毒性会导致严重的并发症和死亡率。早期心脏毒性对治疗结果的影响尚不清楚。JCO近期发表了一篇文章，评估早期心脏毒性的风险因素以及心脏毒性对无事件生存（EFS）和总生存（OS）的影响。

儿童急性髓性白血病治疗后的晚期心脏毒性会导致严重的并发症和死亡率。早期心脏毒性对治疗结果的影响尚不清楚。JCO近期发表了一篇文章，评估早期心脏毒性的风险因素以及心脏毒性对无事件生存（EFS）和总生存（OS）的影响。

研究纳入了AAML0531试验中接受治疗的1，022名患有急性髓性白血病的儿童患者。研究结果表明，约12％的患者在5年的随访期间出现了心脏毒性，超过70％的毒性发生在方案治疗期间。在治疗期间记出现心脏毒性与随后的治疗后毒性显着相关。总体而言，非婴儿和黑人患者以及出现血液感染的患者发病率较高。出现心脏毒性的患者的无事件生存和总生存均较差。与无心脏毒性的患者相比，出现心脏毒性的患者是否合并感染对无事件生存的影响是相似的。但是，出现与感染无关的心脏毒性的患者总生存下降比出现感染有关心脏毒性患者的更严重。

文章最后认为，早期出现治疗相关的心脏毒性可能与无事件生存和总生存降低有关。需要心脏保护措施来降低复发风险并改善短期和长期预后结果。

原始出处：

Kelly D. Getz, Lillian Sung, et al. Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children’s Oncology Group. JCO. October 31 2018 doi: 10.1200/JCO.18.00313

本文系梅斯医学（MedSci）原创编译整理，转载需授权！


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1891560, encodeId=dded189156036, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Jan 13 15:53:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692019, encodeId=fcce1692019ff, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sat Dec 15 14:53:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352039, encodeId=dd693520396b, content=学习了，涨知识了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Fri Nov 09 13:58:25 CST 2018, time=2018-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351978, encodeId=9db83519e858, content=了解一下，谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Nov 08 21:52:46 CST 2018, time=2018-11-08, status=1, ipAttribution=)]
    2019-01-13 lidong40

    #JCO#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1891560, encodeId=dded189156036, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Jan 13 15:53:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692019, encodeId=fcce1692019ff, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sat Dec 15 14:53:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352039, encodeId=dd693520396b, content=学习了，涨知识了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Fri Nov 09 13:58:25 CST 2018, time=2018-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351978, encodeId=9db83519e858, content=了解一下，谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Nov 08 21:52:46 CST 2018, time=2018-11-08, status=1, ipAttribution=)]
    2018-12-15 bnurmamat

    #患者预后#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1891560, encodeId=dded189156036, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Jan 13 15:53:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692019, encodeId=fcce1692019ff, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sat Dec 15 14:53:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352039, encodeId=dd693520396b, content=学习了，涨知识了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Fri Nov 09 13:58:25 CST 2018, time=2018-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351978, encodeId=9db83519e858, content=了解一下，谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Nov 08 21:52:46 CST 2018, time=2018-11-08, status=1, ipAttribution=)]
    2018-11-09 王秀

    学习了，涨知识了！

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1891560, encodeId=dded189156036, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Jan 13 15:53:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692019, encodeId=fcce1692019ff, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sat Dec 15 14:53:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352039, encodeId=dd693520396b, content=学习了，涨知识了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDM9swhbgTo7nzqRKzMmzckmEoeTyLQVDCgjqsicjyhxPs0vPoYU6GsSYbCjSkNHicJkz3NL0a0EbUMVdNjkctXI6FocpGKaVr9E/0, createdBy=29392048316, createdName=王秀, createdTime=Fri Nov 09 13:58:25 CST 2018, time=2018-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351978, encodeId=9db83519e858, content=了解一下，谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Nov 08 21:52:46 CST 2018, time=2018-11-08, status=1, ipAttribution=)]
    2018-11-08 天地飞扬

    了解一下，谢谢分享！

    0

相关资讯

MorphoSys宣布开始3期试验（PROTOSTAR）评估IL-23单抗Guselkumab对银屑病儿童患者的疗效

MorphoSys宣布开始对患有慢性斑块状银屑病的儿科患者进行guselkumab的3期临床试验。根据clinicaltrials.gov，该临床试验PROTOSTAR预计招募约125名年龄在6-18岁患有斑块状银屑病的儿童，并将评估guselkumab与依那西普（TNF-α单抗）和安慰剂相比的功效、安全性和药代动力学。

Sci Rep：舒更葡糖钠：逆转儿童患者术后残余神经肌肉阻滞的有力武器

2017年7月，发表在《Sci Rep》的一项由中国科学家进行的系统评价和荟萃分析，考察了舒更葡糖钠逆转儿童患者术后残余神经肌肉阻滞的有效性和安全性。

JACI Pract：嗜酸细胞性食管炎诊治：成人优于儿童

嗜酸细胞性食管炎是一种以食管嗜酸性粒细胞增多（每高倍视野多于15个嗜酸性粒细胞）为主要特征的疾病，抑酸药治疗无效。多项研究已证实，嗜酸细胞性食管炎患者的临床表现具有年龄差异，但是国际胃肠病研究小组以及美国胃肠病学大学发布的指南对初始治疗以及转诊病人的建议并未有太大区别。 美国Ichan医学院过敏与临床免疫学的Rassbach教授进行了一项研究，提示嗜酸细胞性食管炎的诊断与治疗具有显著年龄

葛文彤：挽救生命的成就感无可替代

六年前，一场强震让青海玉树成为首都的牵挂。六年来，一批又一批北京援建者奔赴高原，重建玉树。如今，站在安宁、祥和的玉树新城，很难想象这些援建者是如何在一片废墟中将它重建成现代之城的。 北京儿童医院副院长葛文彤，是北京第二批援青干部的代表。 “如果没有亲身经历过，很难感受到玉树重建的艰难、百姓生活的不易。”刚从玉树归来不久的葛文彤依然深深牵挂着当地的居民。 智力援助推动玉树重建

J Antimicrob Chemother：肝硬化儿童患者降低卡泊芬净维持剂量 好心办坏事？

2018年9月1日，发表于《J Antimicrob Chemother》上的一项临床试验表明，儿童乙型或丙型肝炎肝硬化患者不需要调整卡泊芬净的剂量。